Acurx Pharmaceuticals (ACXP) Other Non-Current Liabilities (2021 - 2022)
Acurx Pharmaceuticals' (ACXP) quarterly Other Non-Current Liabilities came in at $618000.0 in Q2 2022, little changed on a QoQ basis from $618000.0 in Q1 2022.
Acurx Pharmaceuticals (ACXP) Other Non-Current Liabilities (2021 - 2022) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 2 years of Other Non-Current Liabilities data on file, last reported at $618000.0 in Q2 2022.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $618000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $618000.0 (changed N/A YoY) and the FY2021 annual result came in at $618000.0, changed N/A from the prior year.
- Other Non-Current Liabilities held at $618000.0 in Q2 2022, from $618000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $618000.0 in Q4 2021 to a low of $618000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - |
| 10 | Acurx Pharmaceuticals | 6.39 Mn | 6.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 618,000.00 |
| Mar 31, 2022 | 618,000.00 |
| Dec 31, 2021 | 618,000.00 |